Vaccine Info

REGN-EB3 Ebola

REGN-EB3 Ebola Description

REGN-EB3 is a novel anti-viral antibody cocktail developed using VelociSuite® proprietary rapid response technologies.

REGN-EB3 is an investigational triple antibody cocktail treatment for Ebola virus infection and is currently under Priority Review by the U.S. Food and Drug Administration, with a target action date of October 25, 2020. 

Contingent on FDA approval, Regeneron expects to deliver an established number of treatment doses over the course of six years and receive compensation of approximately $10 million in 2021 and an average of $67 million per year for each of the next five years (2022-2026).

VelociGene enables rapid, automated, and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of modifications. This enables unprecedented speed and capacity for the validation of therapeutic targets and the creation of animal models of human disease. Under the NIH grant, we took on the challenge of targeting 3,500 of the most difficult genes.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

REGN-EB3 News

July 29, 2020 - Regeneron Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services (HHS), has entered into an agreement to procure REGN-EB3 as part of the HHS' goal of building national preparedness for public health emergencies.

July 27, 2020 - Expanded Access Protocol for Treatment of Ebola Virus.

April 17, 2020 - The U.S. Food and Drug Administration has accepted for Priority Review a new Biologics License Application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection.

November 27, 2019 - Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3.

November 26, 2018 - The Ministry of Health of the Democratic Republic of the Congo announced the launching of a randomized clinical trial to evaluate the effectiveness and safety of medications used in the treatment of Ebola patients. 

October 3, 2017 - The US government announced it is expanding the Strategic National Stockpile supply of vaccines and medications to better prepare for an Ebola outbreak.

 

Updated
07/31/2020 - 08:53